What Researchers Did
Researchers reviewed the potential beneficial effects of hyperbaric oxygen therapy (HBOT) as a novel treatment modality for oral submucous fibrosis (OSMF).
What They Found
They found that hyperbaric oxygen therapy (HBOT), involving 100% oxygen inhalation at 2.0 to 2.5 atmospheres for 60 to 120 minutes, could increase oxygen delivery to oxygen-deficient tissues. This therapy also demonstrated potent anti-inflammatory properties, suggesting potential benefits for improving the hypoxic environment and managing oral submucous fibrosis (OSMF) at cellular and molecular levels.
What This Means for Canadian Patients
For Canadian patients suffering from oral submucous fibrosis (OSMF), this review suggests that hyperbaric oxygen therapy (HBOT) could potentially offer a new approach to manage this debilitating condition. If proven effective in clinical trials, HBOT might help improve tissue oxygenation and reduce inflammation, offering a supplementary treatment option where current therapies have inconsistent results.
Canadian Relevance
This review article does not have a direct Canadian connection.
Study Limitations
As a review article, this study primarily discusses the theoretical potential of HBOT for OSMF and does not present new clinical trial data or patient outcomes.